Scholarlink

Purpose of Review <p>This review focuses on the emerging roles of AFP-L3 and DCP as complementary biomarkers to AFP in the diagnosis, management, and surveillance of hepatocellular carcinoma (HCC). We aim to provide a comprehensive overview of their utility in improving HCC outcomes, including early detection, risk stratification, treatment response, and post-transplant monitoring.</p> Recent Findings <p>AFP-L3 and DCP have demonstrated significant utility in augmenting AFP for HCC diagnosis and prognostication. The GALAD score, which integrates AFP, AFP-L3, and DCP, has shown superior sensitivity and specificity for early-stage HCC detection compared to AFP alone. Both biomarkers are predictive of aggressive tumor features, including microvascular invasion, and have shown promise in treatment response monitoring and post-transplant recurrence risk stratification. Emerging models like the LAD score have highlighted their potential to improve sensitivity for viable tumor detection post-treatment.</p> Summary <p>AFP-L3 and DCP represent critical advancements in biomarker-driven management of HCC, offering improved diagnostic accuracy and prognostic capabilities. Standardization of cutoff values and routine inclusion in national databases could enhance their clinical application. Ongoing trials, such as those comparing GALAD to traditional AFP and ultrasound screening, may establish these biomarkers as standard components of HCC management algorithms.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Role of AFP-L3 and DCP Biomarkers in the Diagnosis and Management of Hepatocellular Carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月25日

查看全文
  • Joshua S. Norman,
  • Neil Mehta

摘要

Purpose of Review

This review focuses on the emerging roles of AFP-L3 and DCP as complementary biomarkers to AFP in the diagnosis, management, and surveillance of hepatocellular carcinoma (HCC). We aim to provide a comprehensive overview of their utility in improving HCC outcomes, including early detection, risk stratification, treatment response, and post-transplant monitoring.

Recent Findings

AFP-L3 and DCP have demonstrated significant utility in augmenting AFP for HCC diagnosis and prognostication. The GALAD score, which integrates AFP, AFP-L3, and DCP, has shown superior sensitivity and specificity for early-stage HCC detection compared to AFP alone. Both biomarkers are predictive of aggressive tumor features, including microvascular invasion, and have shown promise in treatment response monitoring and post-transplant recurrence risk stratification. Emerging models like the LAD score have highlighted their potential to improve sensitivity for viable tumor detection post-treatment.

Summary

AFP-L3 and DCP represent critical advancements in biomarker-driven management of HCC, offering improved diagnostic accuracy and prognostic capabilities. Standardization of cutoff values and routine inclusion in national databases could enhance their clinical application. Ongoing trials, such as those comparing GALAD to traditional AFP and ultrasound screening, may establish these biomarkers as standard components of HCC management algorithms.